67 results
Page 2 of 4
S-8
EX-4.2
rm1337jg4j bxupx
25 Feb 21
Registration of securities for employees
4:46pm
6-K
EX-99.1
jx3m343bk32
23 Feb 21
Genmab 2020 Annual Report
12:38pm
6-K
EX-99.1
h4vhoo oa9pdhljz51a
23 Feb 21
Genmab 2020 Annual Report
12:38pm
6-K
EX-99.1
cijyjnc
15 Dec 20
Current report (foreign)
5:17pm
6-K
EX-99.2
bbc7xwg4do jzsi
15 Dec 20
Current report (foreign)
5:17pm
6-K
EX-99.1
r41 9crlj3
24 Nov 20
Genmab Announces Enapotamab Vedotin Update
11:59am
6-K
EX-99.1
6ab8e1b xxxb
10 Nov 20
Capital Increase in Genmab as a Result of Employee Warrant Exercise
3:04pm
6-K
EX-99.1
8ik7mfwkho59
5 Nov 20
Genmab Announces Phase 3 Study Evaluating Epcoritamab in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
11:06am
6-K
EX-99.1
10byycrl
4 Nov 20
Genmab Announces Financial Results for the First Nine Months of 2020
11:48am
6-K
EX-99.1
9w5c84
21 Oct 20
Current report (foreign)
5:06pm
6-K
EX-99.1
ed4d frkxfg3fobuql
14 Oct 20
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2020
4:54pm
6-K
EX-99.1
sl5176 wzwei
30 Sep 20
Current report (foreign)
12:00am
6-K
EX-99.1
jffs5mmi0r1sc
29 Sep 20
Capital Increase in Genmab as a Result of Employee Warrant Exercise
4:02pm
6-K
EX-99.1
38jxbgqq6i
22 Sep 20
Genmab Commences Binding Arbitration of Two Matters Under License Agreement with Janssen
5:14pm
6-K
EX-99.1
fy3y6aw43vcfdy xx
20 Aug 20
Current report (foreign)
5:29pm
6-K
EX-99.1
lghg dyszc
20 Aug 20
Current report (foreign)
5:24pm
6-K
1sqd nrit7k1
20 Aug 20
Current report (foreign)
5:24pm
6-K
EX-99.1
aqzlu rlxh
12 Aug 20
Genmab Announces Financial Results for the First Half of 2020
3:22pm
6-K
EX-99.1
8cywe70r5eiabg6g3
6 May 20
Genmab Announces Financial Results for the First Quarter of 2020
2:31pm
20-F
vz8jzit 6xcvvftlv
30 Mar 20
Annual report (foreign)
5:12pm